KALYTERA THERAPEUTICS INC Kalytera Therapeutics Inc Stock Toronto S.E.
Equities
KLY
CA48349P1036
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| - PTS | -.--% |
|
-.--% | -.--% |
| Sales 2019 | - | Sales 2020 | - | Capitalization | 13.65M 0 |
|---|---|---|---|---|---|
| Net income 2019 | -21M - | Net income 2020 | 4M - | EV / Sales 2019 | - |
| Net Debt 2019 | 704K 0 | Net Debt 2020 | 920K 0 | EV / Sales 2020 | - |
| P/E ratio 2019 |
-0.9
x | P/E ratio 2020 |
3.17
x | Employees | - |
| Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 99.74% |
More Fundamentals
* Assessed data
More news
More press releases
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâs products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
| 1st Jan change | Capi. | |
|---|---|---|
| +0.72% | 43.84B | |
| +5.73% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +5.83% | 25.53B | |
| -25.01% | 18.18B | |
| -3.30% | 12.29B | |
| +25.76% | 12.29B | |
| +6.69% | 11.15B |
- Stock Market
- Equities
- CLAS.H Stock
- KLY Stock
